3D engineered scaffold for large-scale Vigil immunotherapy production.

Humans Tissue Scaffolds / chemistry Immunotherapy / methods Extracellular Matrix Tissue Engineering / methods HCT116 Cells Colorectal Neoplasms / pathology Animals Mice Cell Proliferation Cell Line, Tumor Cell Culture Techniques, Three Dimensional / methods
Autologous tumor cell therapy Cell expansion Immunotherapy Ovarian cancer Vigil

Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
05 Jul 2024
Historique:
received: 04 04 2024
accepted: 26 06 2024
medline: 6 7 2024
pubmed: 6 7 2024
entrez: 5 7 2024
Statut: epublish

Résumé

Previously, we reported successful cellular expansion of a murine colorectal carcinoma cell line (CT-26) using a three-dimensional (3D) engineered extracellular matrix (EECM) fibrillar scaffold structure. CCL-247 were grown over a limited time period of 8 days on 3D EECM or tissue culture polystyrene (TCPS). Cells were then assayed for growth, electroporation efficiency and Vigil manufacturing release criteria. Using EECM scaffolds, we report an expansion of CCL-247 (HCT116), a colorectal carcinoma cell line, from a starting concentration of 2.45 × 10

Identifiants

DOI: 10.1038/s41598-024-65993-3 PMID: 38969656
pubmed: 38969656
doi: 10.1038/s41598-024-65993-3
pii: 10.1038/s41598-024-65993-3
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

15556

Informations de copyright

© 2024. The Author(s).

Références

Maples, P. et al. TAG vaccine: Autologous tumor vaccine genetically modified to express GM-CSF and block production of TGFB2. BioProcess J. 8(1), 38–44 (2009).
doi: 10.12665/J81.Maples.P2
Maples, P. et al. FANG vaccine: Autologous tumor cell vaccine genetically modified to express GM-CSF and block production of furin. BioProcess. J. 8(4), 4–14 (2010).
doi: 10.12665/J84.Maples
Oh, J. et al. Phase II study of Vigil(R) DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer. Gynecol. Oncol. 143(3), 504–510 (2016).
doi: 10.1016/j.ygyno.2016.09.018 pubmed: 27678295
Oh, J. et al. Long-term follow-up of Phase 2A trial results involving advanced ovarian cancer patients treated with Vigil(R) in frontline maintenance. Gynecol. Oncol. Rep. 34, 100648 (2020).
doi: 10.1016/j.gore.2020.100648 pubmed: 33364285 pmcid: 7752749
Rocconi, R. P. et al. Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer. Gynecol. Oncol. 161(3), 676–680 (2021).
doi: 10.1016/j.ygyno.2021.03.009 pubmed: 33715892
Senzer, N. et al. Phase I trial of “bi-shRNAi(furin)/GMCSF DNA/autologous tumor cell” vaccine (FANG) in advanced cancer. Mol. Ther. 20(3), 679–686 (2012).
doi: 10.1038/mt.2011.269 pubmed: 22186789
Senzer, N. et al. Long term follow up: Phase I trial of “bi-shRNA furin/GMCSF DNA/autologous tumor cell” immunotherapy (FANG™) in advanced cancer. J. Vaccines Vaccin. 4(8), 209 (2013).
Walter, A. et al. Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer. Gynecol. Oncol. 163(3), 459–464 (2021).
doi: 10.1016/j.ygyno.2021.10.004 pubmed: 34702567
Rocconi, R. P. et al. Gemogenovatucel-T (Vigil) immunotherapy as maintenance in frontline stage III/IV ovarian cancer (VITAL): A randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Oncol. 21(12), 1661–1672 (2020).
doi: 10.1016/S1470-2045(20)30533-7 pubmed: 33271095
Rocconi, R. P. et al. Long-term follow-up of gemogenovatucel-T (Vigil) survival and molecular signals of immune response in recurrent ovarian cancer. Vaccines (Basel) 9(8), 894 (2021).
doi: 10.3390/vaccines9080894 pubmed: 34452019
Sliheet, E. et al. Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy. Cancer Gene Ther. 29(7), 993–1000 (2022).
doi: 10.1038/s41417-021-00400-x pubmed: 34785763
Rocconi, R. P. et al. ENTPD1/CD39 as a predictive marker of treatment response to gemogenovatucel-T as maintenance therapy in newly diagnosed ovarian cancer. Commun. Med. (Lond.) 2(1), 106 (2022).
doi: 10.1038/s43856-022-00163-y pubmed: 36051466
Steier, A., Muñiz, A., Neale, D. & Lahann, J. Emerging trends in information-driven engineering of complex biological systems. Adv. Mater. 31(26), 1806898 (2019).
doi: 10.1002/adma.201806898
Ma, C., Peng, Y., Li, H. & Chen, W. Organ-on-a-chip: A new paradigm for drug development. Trends Pharmacol. Sci. 42(2), 119–133 (2021).
doi: 10.1016/j.tips.2020.11.009 pubmed: 33341248
Ryu, N.-E., Lee, S.-H. & Park, H. Spheroid culture system methods and applications for mesenchymal stem cells. Cells 8(12), 1620 (2019).
doi: 10.3390/cells8121620 pubmed: 31842346 pmcid: 6953111
Moon, S. et al. A scalable engineered extracellular matrix platform to expand tumor cells. Adv. NanoBiomed Res. 3(8), 2300012 (2023).
doi: 10.1002/anbr.202300012
Jordahl, J. H. et al. 3D jet writing: Functional microtissues based on tessellated scaffold architectures. Adv. Mater. 30(14), 1707196 (2018).
doi: 10.1002/adma.201707196
Moon, S. et al. 3D jet writing of mechanically actuated tandem scaffolds. Sci. Adv. 7(16), eabf5289 (2021).
doi: 10.1126/sciadv.abf5289 pubmed: 33853783 pmcid: 8046364
Lee, J. et al. Facile fabrication of anisotropic multicompartmental microfibers using charge reversal electrohydrodynamic co-jetting. Macromol. Rapid Commun. 43(1), e2100560 (2022).
doi: 10.1002/marc.202100560 pubmed: 34643980
Muniz, A. J. et al. Engineered extracellular matrices facilitate brain organoids from human pluripotent stem cells. Ann. Clin. Transl. Neurol. 10(7), 1239–1253 (2023).
doi: 10.1002/acn3.51820 pubmed: 37283238 pmcid: 10351667
Jordahl, S. et al. Engineered fibrillar fibronectin networks as three-dimensional tissue scaffolds. Adv. Mater. 31(46), e1904580 (2019).
doi: 10.1002/adma.201904580 pubmed: 31565823 pmcid: 6851443
Sato, Y., Fu, Y., Liu, H., Lee, M. Y. & Shaw, M. H. Tumor-immune profiling of CT-26 and Colon 26 syngeneic mouse models reveals mechanism of anti-PD-1 response. BMC Cancer 21(1), 1222 (2021).
doi: 10.1186/s12885-021-08974-3 pubmed: 34774008 pmcid: 8590766
Gong, X. et al. A resazurin-based, nondestructive assay for monitoring cell proliferation during a scaffold-based 3D culture process. Regen. Biomater. 7(3), 271–281 (2020).
doi: 10.1093/rb/rbaa002 pubmed: 32523729 pmcid: 7266666
Ravi, M., Paramesh, V., Kaviya, S. R., Anuradha, E. & Solomon, F. D. P. 3D cell culture systems: Advantages and applications. J. Cell. Physiol. 230(1), 16–26 (2015).
doi: 10.1002/jcp.24683 pubmed: 24912145
Shyam, R., Reddy, L. V. K. & Palaniappan, A. Fabrication and characterization techniques of in vitro 3D tissue models. Int. J. Mol. Sci. 24(3), 1912 (2023).
doi: 10.3390/ijms24031912 pubmed: 36768239 pmcid: 9915354
Nemunaitis, J. et al. Clonal neoantigen: Emerging “mechanism-based” biomarker of immunotherapy response. Cancers (Basel) 15(23), 5616 (2023).
doi: 10.3390/cancers15235616 pubmed: 38067319
Rappaport, A. R. et al. A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: Phase 1 trial interim results. Nat. Med. 30(4), 1013–1022 (2024).
doi: 10.1038/s41591-024-02851-9 pubmed: 38538867
Weber, J. S. et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): A randomised, phase 2b study. Lancet 403(10427), 632–644 (2024).
doi: 10.1016/S0140-6736(23)02268-7 pubmed: 38246194
McGranahan, N. et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351(6280), 1463–1469 (2016).
doi: 10.1126/science.aaf1490 pubmed: 26940869 pmcid: 4984254
Rosenthal, R. et al. Neoantigen-directed immune escape in lung cancer evolution. Nature 567(7749), 479–485 (2019).
doi: 10.1038/s41586-019-1032-7 pubmed: 30894752 pmcid: 6954100
Litchfield, K. et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell 184(3), 596-614 e14 (2021).
doi: 10.1016/j.cell.2021.01.002 pubmed: 33508232 pmcid: 7933824
Rizvi, N. A. et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348(6230), 124–128 (2015).
doi: 10.1126/science.aaa1348 pubmed: 25765070 pmcid: 4993154
Boll, L. M. et al. The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer. Sci. Rep. 13(1), 15287 (2023).
doi: 10.1038/s41598-023-42495-2 pubmed: 37714872 pmcid: 10504302
Riaz, N. et al. Tumor and microenvironment. Evolution during Immunotherapy with Nivolumab. Cell 171(4), 934-949 e16 (2017).
doi: 10.1016/j.cell.2017.09.028 pubmed: 29033130 pmcid: 5685550
Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371(23), 2189–2199 (2014).
doi: 10.1056/NEJMoa1406498 pubmed: 25409260 pmcid: 4315319

Auteurs

Fabienne Kerneis (F)

Gradalis, Inc, Dallas, TX, 75006, USA.

Ernest Bognar (E)

Gradalis, Inc, Dallas, TX, 75006, USA.

Laura Stanbery (L)

Gradalis, Inc, Dallas, TX, 75006, USA.

Seongjun Moon (S)

University of Michigan Biointerfaces Institute, Ann Arbor, MI, 48109, USA.

Do Hoon Kim (DH)

University of Michigan Biointerfaces Institute, Ann Arbor, MI, 48109, USA.

Yuxuan Deng (Y)

University of Michigan Biointerfaces Institute, Ann Arbor, MI, 48109, USA.

Elliot Hughes (E)

University of Michigan Biointerfaces Institute, Ann Arbor, MI, 48109, USA.

Tae-Hwa Chun (TH)

University of Michigan Biointerfaces Institute, Ann Arbor, MI, 48109, USA.
Department of Metabolism, Endocrinology and Diabetes, University of Michigan Medical School, Ann Arbor, MI, 48109, USA.

Darron Tharp (D)

Gradalis, Inc, Dallas, TX, 75006, USA.

Heidi Zupanc (H)

Gradalis, Inc, Dallas, TX, 75006, USA.

Chris Jay (C)

Gradalis, Inc, Dallas, TX, 75006, USA.

Adam Walter (A)

Gradalis, Inc, Dallas, TX, 75006, USA.
Department of Gynecologic Oncology, Promedica, Toledo, OH, 43560, USA.

John Nemunaitis (J)

Gradalis, Inc, Dallas, TX, 75006, USA. jnemunaitis@gradalisinc.com.

Joerg Lahann (J)

University of Michigan Biointerfaces Institute, Ann Arbor, MI, 48109, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › 3D engineered scaffold for large-scale Vigil...
questionsmedicales.fr › Équipement et fournitures › Prothèses et implants › Structures d'échafaudage tissulaires › 3D engineered scaffold for large-scale Vigil...
questionsmedicales.fr › Thérapeutique › Biothérapie › Immunothérapie › 3D engineered scaffold for large-scale Vigil...
questionsmedicales.fr › Cellules › Structures cellulaires › Espace extracellulaire › Matrice extracellulaire › 3D engineered scaffold for large-scale Vigil...
questionsmedicales.fr › Technologie, industrie et agriculture › Ingénierie › Bioingénierie › Ingénierie cellulaire › Ingénierie tissulaire › 3D engineered scaffold for large-scale Vigil...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Cellules HCT116 › 3D engineered scaffold for large-scale Vigil...
questionsmedicales.fr › Maladies de l'appareil digestif › Maladies gastro-intestinales › Maladies intestinales › Maladies du rectum › Tumeurs colorectales › 3D engineered scaffold for large-scale Vigil...
questionsmedicales.fr › Eucaryotes › Animaux › 3D engineered scaffold for large-scale Vigil...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › 3D engineered scaffold for large-scale Vigil...
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Processus de croissance cellulaire › Prolifération cellulaire › 3D engineered scaffold for large-scale Vigil...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › 3D engineered scaffold for large-scale Vigil...
questionsmedicales.fr › Techniques d'investigation › Techniques in vitro › Techniques de culture › Techniques de culture cellulaire › Techniques de cultures cellulaires tridimensionnelles › 3D engineered scaffold for large-scale Vigil...